Lupin is currently trading at Rs. 1939.00, up by 9.25 points or 0.48% from its previous closing of Rs. 1929.75 on the BSE.

The scrip opened at Rs. 1954.95 and has touched a high and low of Rs. 1954.95 and Rs. 1938.70 respectively. So far 3882 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 2403.45 on 02-Jan-2025 and a 52 week low of Rs. 1767.20 on 22-Jul-2024.

Last one week high and low of the scrip stood at Rs. 1959.00 and Rs. 1875.65 respectively. The current market cap of the company is Rs. 88815.30 crore.

The promoters holding in the company stood at 46.92%, while Institutions and Non-Institutions held 46.88% and 6.20% respectively.

Lupin has launched Loteprednol Etabonate Ophthalmic Suspension, 0.5%, in the United States (U.S.). Loteprednol Etabonate Ophthalmic Suspension, 0.5% is bioequivalent to Lotemax Ophthalmic Suspension, 0.5%, of Bausch & Lomb Inc. 

Loteprednol Etabonate Ophthalmic Suspension, 0.5% is indicated for the treatment of steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitides, when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation. 

It is also indicated for the treatment of post-operative inflammation following ocular surgery. Loteprednol Etabonate Ophthalmic Suspension (RLD Lotemax) had estimated annual sales of $55 million in the U.S. (IQVIA MAT May 2025).

Lupin is an innovation led transnational pharmaceutical company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.